{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:51:18Z","timestamp":1791010278966,"version":"4.1.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T00:00:00Z","timestamp":1301443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3,30]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>The introduction of cyclophosphamide (CyP) as a treatment for Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) has been among the most significant contributions in vasculitis. Prior to the introduction of CyP, WG was a uniformly fatal disease, with mortality occurring within 5\u201312 months from pulmonary or renal failure or from infection due to glucocorticoids. In 1973 Fauci and Wolff, at the National Institutes of Health, published their experience with a regimen that combined CyP and prednisone in which disease remission was seen in 12 of 14 patients. Long-term experience with CyP provided even greater evidence for its efficacy in which an 80% survival rate was seen, with 91% of patients having significant improvement and 75% achieving complete remission. However, extended follow-up also demonstrated that disease relapse occurred in at least 50% of patients and that 42% experienced morbidity solely as a result of treatment. These observations showed that while CyP was life-saving, it did not prevent relapse and was associated with significant toxicity such that safer means to induce remission needed to be pursued. Strategies aimed at reducing exposure to CyP have included intermittent administration, induction\u2013maintenance regimens and avoidance of CyP for non-severe disease. Recently, the introduction of rituximab has raised important questions regarding the place of CyP in the treatment of WG\/MPA. This paper examines the past, present and future of CyP through a review of its efficacy and safety.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2011.04364.x","type":"journal-article","created":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T10:48:54Z","timestamp":1301482134000},"page":"31-34","source":"Crossref","is-referenced-by-count":50,"title":["Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis"],"prefix":"10.1093","volume":"164","author":[{"given":"C A","family":"Langford","sequence":"first","affiliation":[{"name":"Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,3,30]]},"reference":[{"key":"2021122708481045400_b1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00005792-197311000-00002","article-title":"Wegener's granulomatosis: studies in eighteen patients and a review of the literature","volume":"52","author":"Fauci","year":"1973","journal-title":"Medicine"},{"key":"2021122708481045400_b2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"key":"2021122708481045400_b3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"2021122708481045400_b4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0002-9343(90)90367-M","article-title":"Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide","volume":"89","author":"Hoffman","year":"1990","journal-title":"Am J Med"},{"key":"2021122708481045400_b5","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","article-title":"A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis","volume":"40","author":"Guillevin","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2021122708481045400_b6","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1136\/ard.2010.131953","article-title":"Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021122708481045400_b7","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"2021122708481045400_b8","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/1529-0131(199912)42:12<2666::AID-ANR24>3.0.CO;2-E","article-title":"A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance","volume":"42","author":"Langford","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2021122708481045400_b9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122708481045400_b10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/MD.0b013e3181568ec0","article-title":"Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience","volume":"86","author":"Villa-Forte","year":"2007","journal-title":"Medicine"},{"key":"2021122708481045400_b11","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122708481045400_b12","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"2021122708481045400_b13","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021122708481045400_b14","first-page":"795","article-title":"Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis","volume":"151","author":"Ognibene","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"2021122708481045400_b15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Ann Intern Med"},{"key":"2021122708481045400_b16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-126-4-199702150-00005","article-title":"Use of testosterone to prevent cyclophosphamide-induced azoospermia","volume":"126","author":"Masala","year":"1997","journal-title":"Ann Intern Med"},{"key":"2021122708481045400_b17","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/art.21263","article-title":"Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus","volume":"52","author":"Somers","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021122708481045400_b18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122708481045400_b19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2011.04364.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/164\/Supplement_1\/31\/41909367\/j.1365-2249.2011.04364.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/164\/Supplement_1\/31\/41909367\/j.1365-2249.2011.04364.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:25:47Z","timestamp":1641054347000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/164\/Supplement_1\/31\/6438888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,30]]},"references-count":19,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2011,3,30]]},"published-print":{"date-parts":[[2011,3,30]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2011.04364.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,5]]},"published":{"date-parts":[[2011,3,30]]}}}